Psoriasis

Researchers explored the potential causal relationship between pure hypercholesterolemia, a recognized risk factor for cardiovascular disease, and psoriasis.

The US license period will start on February 22, 2025.

Depression, functional impairment, and worsened quality of life are related in patients with psoriatic disease, according to a recent study.

Because of the chronic inflammatory state of psoriasis and the immunosuppression produced by some systemic medications, patients with psoriasis may have an increased risk of lymphoma and nonmelanoma skin cancer.

Label warnings may affect the initiation of new treatment and real-world switching patterns for psoriasis patients starting treatment with risankizumab.

Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.

In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.

Investigators noted that patients with mild psoriasis experience a less favorable status when compared to patients with moderate psoriasis.

PASI scores were significantly correlated with sleep quality, duration, and disturbances.

Authors of the case report that little is known about the associations between psoriasis and renal function.

The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.

Leah Howard, JD, of the National Psoriasis Foundation, discusses the importance of advocacy in psoriasis, the role of mental health in chronic skin conditions, and the role of support organizations in advocating for awareness and health equity.

Once daily application of tapinarof cream 1% rapidly improved itch in adult patients with varying plaque psoriasis diseases severity, according to a poster presented at SDPA’s fall conference.

Douglas DiRuggiero, DMSc, PA-C, presented a comprehensive session at the SDPA fall conference on treatment selection for patients with psoriasis.

Black and male patients exhibited a higher prevalence of palmoplantar psoriasis when compared with White patients.

82.8% of adult patients with iPsO achieved an IGA score of 0 or 1 indicative of complete or almost complete lesion clearance.

Topline results from the phase 3b trial revealed significant improvements in patients with skin of color whose psoriasis was treated with guselkumab.

Bimekizumab is now the first and only approved IL-17A and IL-17F inhibitor for this indication.

At week 8, 65.3% of roflumilast-treated patients achieved a clinically significant reduction in itch.

Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, share their approaches to educating patients on use of steroids for dermatologic conditions, highlighting how they approach pediatric patient populations.

Experts in dermatology discuss the benefits of improved topical steroidal vehicle excipients and their impact on treatment duration and response.

Linda F. Stein Gold, MD; Jayme M. Heim, MSN, FNP-BC; and Darren West, MPAS, PA-C, review the adverse effect profiles of steroidal and nonsteroidal treatments, focusing on hypothalamic pituitary adrenal axis suppression.

Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, comment on how steroids continue to fit into the topical treatment armamentarium.

Experts discuss the treatment landscape of generalized pustular psoriasis as well as review difficult cases of GPP.

Protagonist Therapeutics has just announced the company's eligibility to receive $60 million of milestone payments for JNJ-2113 to enter into clinical development programs led by Janssen.

The approval provides pediatric patients with a steroid-free topical therapy.

Boni Elewski, MD, shares resources for patients with GPP, highlighting a team-based approach to meet the psychological and physical needs of the patient.

Drs Raj Chovatiya and Boni Elewski comment on the future of combination therapy in GPP, highlighting spesolimab.